Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
Are there any trials looking at alternative treatments for patients who otherwise would receive 2 years of ADT but have the HSD3B1 gene (homozygous vs heterozygous)?
Related Questions
Would you use fezolinetant for hot flashes for men on ADT?
How do you sequence Ra-223 and Lu-177 in patients with mCRPC with predominantly bony disease?
What are your top takeaways from ASCO GU 2024?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
What is your approach to a patient with muscle invasive bladder cancer getting neoadjuvant gemcitabine/cisplatin who develops significant ototoxicity due to cisplatin after two cycles?
How often do you offer repeat imaging for patients with life expectancy>10 years and BCR prostate cancer with PSADT>10 months while they are on observation?
What is the optimal sequence of available therapies in patients with BRCA+/HRR mCRPC after progression on first line combinations?
Are patients with MIBC and bladder neck involvement good candidates for bladder preservation with chemoradiation after maximal, but not complete, TURBT?
What duration androgen deprivation do you recommend with salvage pelvic radiotherapy for pelvic node relapse after prostatectomy?
If a patient diagnosed with seminoma after orchiectomy has margin positive disease noted in the spermatic cord and no overt metastasis on imaging and normal tumor markers, how should this patient be staged?
